Belying its small size, the Nordic nation of Sweden punches well above its weight in scientific innovation. Despite boasting a population of just 10 million and a marginal position on the most northerly fringes of the EU, Sweden has been ranked the second most innovative country in the world by the World Intellectual Property Organization and first in Europe by the European Commission.
Nowhere is this Swedish spirit of innovation more keenly felt than in the country’s healthcare and life sciences industry. The nation that introduced some of the most impactful healthcare inventions of the 20th century – including the implantable pacemaker, the first artificial kidney, the respirator, and the gamma knife – Sweden and its USD 4.8 billion pharma market are at the forefront of a number of key industry trends.
Through the exclusive insights of multinational affiliate leaders, heads of local champions, and representatives from Sweden’s dense network of top-class academic institutions, this report paints a picture of the unique spirit of collaboration that pervades the nation’s healthcare and life sciences industry.
Other topics covered include how Sweden is aiming to regain its place as one of the world’s leading clinical trials destinations, the ways in which stakeholders across the board are leveraging the treasure trove of data contained in the country’s National Quality Registries, the cutting-edge digital healthcare solutions being implemented in Swedish hospitals, and how multinational firms are increasingly using Sweden as a test-bed market for their latest treatments.
The report also looks at Sweden’s pioneering work in regulatory science, its world-leading cancer care, why the country is seeing a boom in its contract research industry, and how it is fast staking a claim as one of Europe’s premier biotech hotspots.